Abstract
The use of medical therapies that target established atherosclerotic risk factors has had a profound impact on the incidence of cardiovascular events. However, the majority of clinical events are not prevented. This highlights the need to identify new therapeutic targets to achieve further clinical benefit. A number of pathological events within the arterial wall, which contribute to atheroma formation, represent potential targets for therapeutic intervention. The use of surrogate markers of clinical efficacy has become increasingly popular in the assessment of novel therapies. Imaging of atherosclerotic plaques and their progression by intravascular ultrasound has been used in a number of studies to evaluate therapeutic strategies. Using this analytical approach, in the recently reported acyl cholesteryly acyl transferase intravascular atherosclerosis treatment evaluation (ACTIVATE) study, the experimental acyl-coenzyme:cholesterol acyltransferase inhibitor, pactimibe, was reported to have a detrimental ...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
